Keywords
Last Name
Institution

THOMAS W BURKE

TitleProfessor
InstitutionMD Anderson
DepartmentGynecological Oncology & Reproductive Medicine
Address1155 Pressler St
HOUSTON TX 77030-3721
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Callegaro-Filho D, Burke TW, Eifel PJ, Ramirez PT, Euscher EE, Schmeler KM. Radiotherapy for recurrent small cell carcinoma of the ovary: A case report and review of the literature. Gynecol Oncol Rep. 2015 Jan; 11:23-5. PMID: 26076089.
      View in: PubMed
    2. Walters RS, Albright HW, Weber RS, Feeley TW, Hanna EY, Cantor SB, Lewis CM, Burke TW. Developing a system to track meaningful outcome measures in head and neck cancer treatment. Head Neck. 2014 Feb; 36(2):226-30. PMID: 23729280.
      View in: PubMed
    3. Simeone WJ, Bingham J, Burke TW, Pisters PW. Quality assessment across a national cancer network. J Oncol Pract. 2013 May; 9(3):165-8. PMID: 23942501.
      View in: PubMed
    4. Jhingran A, Ramondetta LM, Bodurka DC, Slomovitz BM, Brown J, Levy LB, Garcia ME, Eifel PJ, Lu KH, Burke TW. A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol. 2013 May; 129(2):304-9. PMID: 23385150.
      View in: PubMed
    5. Ross W, Lynch P, Raju G, Rodriguez A, Burke T, Hafemeister L, Hawk E, Wu X, Dubois RN, Mishra L. Biomarkers, bundled payments, and colorectal cancer care. Genes Cancer. 2012 Jan; 3(1):16-22. PMID: 22893787.
      View in: PubMed
    6. Spinks T, Albright HW, Feeley TW, Walters R, Burke TW, Aloia T, Bruera E, Buzdar A, Foxhall L, Hui D, Summers B, Rodriguez A, Dubois R, Shine KI. Ensuring quality cancer care: a follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in America. Cancer. 2012 May 15; 118(10):2571-82. PMID: 22045610.
      View in: PubMed
    7. Lacour RA, Euscher E, Atkinson EN, Sun CC, Ramirez PT, Coleman RL, Brown J, Gano JB, Burke TW, Ramondetta LM. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer. 2011 Apr; 21(3):517-22. PMID: 21436700.
      View in: PubMed
    8. Spinks TE, Walters R, Feeley TW, Albright HW, Jordan VS, Bingham J, Burke TW. Improving cancer care through public reporting of meaningful quality measures. Health Aff (Millwood). 2011 Apr; 30(4):664-72. PMID: 21471487.
      View in: PubMed
    9. Albright HW, Moreno M, Feeley TW, Walters R, Samuels M, Pereira A, Burke TW. The implications of the 2010 Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act on cancer care delivery. Cancer. 2011 Apr 15; 117(8):1564-74. PMID: 21472704.
      View in: PubMed
    10. Feeley TW, Fly HS, Albright H, Walters R, Burke TW. A method for defining value in healthcare using cancer care as a model. J Healthc Manag. 2010 Nov-Dec; 55(6):399-411; discussion 411-2. PMID: 21166323.
      View in: PubMed
    11. Slomovitz BM, Lu KH, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, Wolf J. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010 Dec 1; 116(23):5415-9. PMID: 20681032.
      View in: PubMed
    12. Ramondetta LM, Johnson AJ, Sun CC, Atkinson N, Smith JA, Jung MS, Broaddus R, Iyer RB, Burke T. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer. 2009 May 1; 115(9):1867-74. PMID: 19241422.
      View in: PubMed
    13. Burke T, Chalas E. New membership model. Gynecol Oncol. 2009 Jan; 112(1):4-5. PMID: 19100915.
      View in: PubMed
    14. Burke TW. The origins of multidisciplinary cancer care. Gynecol Oncol. 2008 Sep; 110(3 Suppl 2):S2-3. PMID: 18785320.
      View in: PubMed
    15. Lu KH, Wu W, Dave B, Slomovitz BM, Burke TW, Munsell MF, Broaddus RR, Walker CL. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin Cancer Res. 2008 May 1; 14(9):2543-50. PMID: 18451215.
      View in: PubMed
    16. Navo MA, Smith JA, Gaikwad A, Burke T, Brown J, Ramondetta LM. In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines. Cancer Chemother Pharmacol. 2008 Aug; 62(3):483-9. PMID: 18004570.
      View in: PubMed
    17. Frumovitz M, Bodurka DC, Broaddus RR, Coleman RL, Sood AK, Gershenson DM, Burke TW, Levenback CF. Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol. 2007 Jan; 104(1):100-3. PMID: 16963111.
      View in: PubMed
    18. Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol. 2006 Oct; 103(1):155-9. PMID: 16545437.
      View in: PubMed
    19. Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, Levenback CF, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol. 2006 Apr; 101(1):126-31. PMID: 16271384.
      View in: PubMed
    20. Straughn JM, Numnum TM, Kilgore LC, Partridge EE, Phillips JL, Markman M, Thomas GM, Burke TW. The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: a patient care evaluation study from the American College of Surgeons National Cancer Data Base. Gynecol Oncol. 2005 Dec; 99(3):530-5. PMID: 16198401.
      View in: PubMed
    21. Rubatt JM, Slomovitz BM, Burke TW, Broaddus RR. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia. Gynecol Oncol. 2005 Nov; 99(2):472-6. PMID: 16099019.
      View in: PubMed
    22. Lee CM, Slomovitz BM, Greer M, Sharma S, Gregurich MA, Burke T, Lu KH, Ramondetta LM. Practice patterns of SGO members for stage IIIA endometrial cancer. Gynecol Oncol. 2005 Jul; 98(1):77-83. PMID: 15907988.
      View in: PubMed
    23. Brown J, Shvartsman HS, Deavers MT, Ramondetta LM, Burke TW, Munsell MF, Gershenson DM. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol. 2005 May; 97(2):489-96. PMID: 15863149.
      View in: PubMed
    24. Slomovitz BM, Ramondetta LM, Lee CM, Oh JC, Eifel PJ, Jhingran A, Burke TW, Gershenson DM, Lu KH. Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy. Int J Gynecol Cancer. 2005 May-Jun; 15(3):510-6. PMID: 15882178.
      View in: PubMed
    25. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005 Mar; 105(3):575-80. PMID: 15738027.
      View in: PubMed
    26. See HT, Freedman RS, Kudelka AP, Burke TW, Gershenson DM, Tangjitgamol S, Kavanagh JJ. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer. 2005 Mar-Apr; 15(2):209-16. PMID: 15823101.
      View in: PubMed
    27. Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen LM, Allen B, Conrad P, Terdiman J, Sun C, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005 Mar; 105(3):569-74. PMID: 15738026.
      View in: PubMed
    28. Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol. 2004 Oct; 95(1):32-6. PMID: 15385107.
      View in: PubMed
    29. Brown J, Shvartsman HS, Deavers MT, Burke TW, Munsell MF, Gershenson DM. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol. 2004 Sep 1; 22(17):3517-23. PMID: 15337800.
      View in: PubMed
    30. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004 Aug 1; 22(15):3126-32. PMID: 15284264.
      View in: PubMed
    31. Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW, Levenback CF, Wolf JK, Bast RC, Freedman RS, Ippoliti C, Brewer M, Gajewski JL, Gershenson DM. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant. 2004 Jun; 33(12):1219-24. PMID: 15122311.
      View in: PubMed
    32. Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys. 2004 May 1; 59(1):168-73. PMID: 15093913.
      View in: PubMed
    33. Oh JC, Wu W, Tortolero-Luna G, Broaddus R, Gershenson DM, Burke TW, Schmandt R, Lu KH. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2004 May; 13(5):748-52. PMID: 15159305.
      View in: PubMed
    34. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004 Mar 1; 58(3):786-96. PMID: 14967435.
      View in: PubMed
    35. Frumovitz M, Ramirez PT, Tortolero-Luna G, Malpica A, Eifel P, Burke TW, Levenback C. Characteristics of recurrence in patients who underwent lymphatic mapping for vulvar cancer. Gynecol Oncol. 2004 Jan; 92(1):205-10. PMID: 14751159.
      View in: PubMed
    36. Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, Oh JC, Atkinson EN, Broaddus RR, Gershenson DM, Lu KH. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003 Dec; 91(3):463-9. PMID: 14675663.
      View in: PubMed
    37. Ramondetta LM, Burke TW, Jhingran A, Schmandt R, Bevers MW, Wolf JK, Levenback CF, Broaddus R. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets. Gynecol Oncol. 2003 Sep; 90(3):529-36. PMID: 13678720.
      View in: PubMed
    38. Gordinier ME, Malpica A, Burke TW, Bodurka DC, Wolf JK, Jhingran A, Ramirez PT, Levenback C. Groin recurrence in patients with vulvar cancer with negative nodes on superficial inguinal lymphadenectomy. Gynecol Oncol. 2003 Sep; 90(3):625-8. PMID: 13678736.
      View in: PubMed
    39. Burke TW, Walker CL. Arzoxifene as therapy for endometrial cancer. Gynecol Oncol. 2003 Aug; 90(2 Pt 2):S40-6. PMID: 12928005.
      View in: PubMed
    40. Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys. 2003 Aug 1; 56(5):1366-72. PMID: 12873682.
      View in: PubMed
    41. Brown J, Broaddus R, Koeller M, Burke TW, Gershenson DM, Bodurka DC. Sarcomatoid carcinoma of the cervix. Gynecol Oncol. 2003 Jul; 90(1):23-8. PMID: 12821337.
      View in: PubMed
    42. McMeekin DS, Gordon A, Fowler J, Melemed A, Buller R, Burke T, Bloss J, Sabbatini P. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol. 2003 Jul; 90(1):64-9. PMID: 12821343.
      View in: PubMed
    43. Kabbani W, Deavers MT, Malpica A, Burke TW, Liu J, Ordoñez NG, Jhingran A, Silva EG. Uterine tumor resembling ovarian sex-cord tumor: report of a case mimicking cervical adenocarcinoma. Int J Gynecol Pathol. 2003 Jul; 22(3):297-302. PMID: 12819400.
      View in: PubMed
    44. Munkarah AR, Jhingran A, Iyer RB, Wallace S, Eifel PJ, Gershenson D, Burke TW. Utility of lymphangiography in the prediction of lymph node metastases in patients with cervical cancer. Int J Gynecol Cancer. 2002 Nov-Dec; 12(6):755-9. PMID: 12445255.
      View in: PubMed
    45. Holtz D, Ramondetta LM, Burke TW, Palazzo JP, Dunton CJ, Atkinson EN, Broaddus RR. PTEN expression in tamoxifen-associated endometrial cancers. Anticancer Res. 2002 Sep-Oct; 22(5):2945-8. PMID: 12530022.
      View in: PubMed
    46. Ramondetta LM, Silva EG, Levenback CF, Burke TW. Mixed choriocarcinoma in a postmenopausal patient. Int J Gynecol Cancer. 2002 May-Jun; 12(3):312-6. PMID: 12060455.
      View in: PubMed
    47. Levenback C, Coleman RL, Burke TW, Lin WM, Erdman W, Deavers M, Delpassand ES. Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol. 2002 Feb 1; 20(3):688-93. PMID: 11821449.
      View in: PubMed
    48. Levenback C, Coleman RL, Burke TW, Bodurka-Bevers D, Wolf JK, Gershenson DM. Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol. 2001 Nov; 83(2):276-81. PMID: 11606084.
      View in: PubMed
    49. Ramirez PT, Ramondetta LM, Burke TW, Gershenson DM, Brewer MA. Metastatic uterine papillary serous carcinoma to the pericardium. Gynecol Oncol. 2001 Oct; 83(1):135-7. PMID: 11585425.
      View in: PubMed
    50. Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC, Gajewski JL, Champlin RE. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol. 2001 Sep; 82(3):420-6. PMID: 11520135.
      View in: PubMed
    51. Ramirez PT, Levenback C, Burke TW, Eifel P, Wolf JK, Gershenson DM. Sigmoid perforation following radiation therapy in patients with cervical cancer. Gynecol Oncol. 2001 Jul; 82(1):150-5. PMID: 11426977.
      View in: PubMed
    52. Ramondetta L, Burke TW, Levenback C, Bevers M, Bodurka-Bevers D, Gershenson DM. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol. 2001 Jul; 82(1):156-61. PMID: 11426978.
      View in: PubMed
    53. Lu KH, Burke TW. Early cervical cancer. Curr Treat Options Oncol. 2000 Jun; 1(2):147-55. PMID: 12057052.
      View in: PubMed
    54. Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin RE. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant. 2000 Jun; 25(11):1137-40. PMID: 10849525.
      View in: PubMed
    55. Ramondetta L, Mills GB, Burke TW, Wolf JK. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer. Clin Cancer Res. 2000 Jan; 6(1):278-84. PMID: 10656459.
      View in: PubMed
    56. Pustilnik T, Burke TW. Adjuvant chemotherapy for high-risk endometrial cancer. Semin Radiat Oncol. 2000 Jan; 10(1):23-8. PMID: 10671655.
      View in: PubMed
    57. Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Cancer. 1999 Dec 1; 86(11):2291-300. PMID: 10590370.
      View in: PubMed
    58. Wolf JK, Mullen J, Eifel PJ, Burke TW, Levenback C, Gershenson DM. Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Gynecol Oncol. 1999 Apr; 73(1):35-41. PMID: 10094877.
      View in: PubMed
    59. Lin PS, Gershenson DM, Bevers MW, Lucas KR, Burke TW, Silva EG. The current status of surgical staging of ovarian serous borderline tumors. Cancer. 1999 Feb 15; 85(4):905-11. PMID: 10091769.
      View in: PubMed
    60. Gershenson DM, Burke TW, Morris M, Bast RC, Guaspari A, Hohneker J, Wharton JT. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol. 1998 Sep; 70(3):404-9. PMID: 9790795.
      View in: PubMed
    61. Ijaz T, Eifel PJ, Burke T, Oswald MJ. Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma. Gynecol Oncol. 1998 Aug; 70(2):241-6. PMID: 9740698.
      View in: PubMed
    62. Morris M, Brader KR, Burke TW, Levenback CF, Gershenson DM. A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix. Gynecol Oncol. 1998 Aug; 70(2):215-8. PMID: 9740693.
      View in: PubMed
    63. Gershenson DM, Silva EG, Levy L, Burke TW, Wolf JK, Tornos C. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer. 1998 Mar 15; 82(6):1096-103. PMID: 9506355.
      View in: PubMed
    64. Morris M, Brader KR, Levenback C, Burke TW, Atkinson EN, Scott WR, Gershenson DM. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol. 1998 Mar; 16(3):1094-8. PMID: 9508195.
      View in: PubMed
    65. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, Wall M, Harris R, Jones J, Buzaid A, Robertson C, Shenaq S, Curling P, Burke T, Ericsson C. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med. 1997 Aug 15; 127(4):267-74. PMID: 9265425.
      View in: PubMed
    66. Burke TW. How should we monitor women treated for endometrial carcinoma? Gynecol Oncol. 1997 Jun; 65(3):377-8. PMID: 9190959.
      View in: PubMed
    67. Morris M, Levenback C, Burke TW, Dejesus Y, Lucas KR, Gershenson DM. An outcomes management program in gynecologic oncology. Obstet Gynecol. 1997 Apr; 89(4):485-92. PMID: 9083300.
      View in: PubMed
    68. Munkarah AR, Hallum AV, Morris M, Burke TW, Levenback C, Atkinson EN, Wharton JT, Gershenson DM. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol. 1997 Jan; 64(1):13-7. PMID: 8995541.
      View in: PubMed
    69. Ratliff CR, Gershenson DM, Morris M, Burke TW, Levenback C, Schover LR, Mitchell MF, Atkinson EN, Wharton JT. Sexual adjustment of patients undergoing gracilis myocutaneous flap vaginal reconstruction in conjunction with pelvic exenteration. Cancer. 1996 Nov 15; 78(10):2229-35. PMID: 8918419.
      View in: PubMed
    70. Levenback C, Burke TW, Rubin SC, Curtin JP, Wharton JT. Arterial occlusion complicating treatment of gynecologic cancer: a case series. Gynecol Oncol. 1996 Oct; 63(1):40-6. PMID: 8898166.
      View in: PubMed
    71. Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW, Grendys EC. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol. 1996 Oct; 63(1):25-7. PMID: 8898163.
      View in: PubMed
    72. Segreti EM, Morris M, Levenback C, Lucas KR, Gershenson DM, Burke TW. Transverse colon urinary diversion in gynecologic oncology. Gynecol Oncol. 1996 Oct; 63(1):66-70. PMID: 8898171.
      View in: PubMed
    73. Burke TW, Gershenson DM. Chemotherapy as adjuvant and salvage treatment in women with endometrial carcinoma. Clin Obstet Gynecol. 1996 Sep; 39(3):716-27. PMID: 8862895.
      View in: PubMed
    74. Sherertz RJ, Heard SO, Raad II, Gentry L, Bowton D, Scuderi P, Hu J, Carruth W, Satishchandra B, Pepe J, Mosenthal A, Burke T, Dupuis J. Gamma radiation-sterilized, triple-lumen catheters coated with a low concentration of chlorhexidine were not efficacious at preventing catheter infections in intensive care unit patients. Antimicrob Agents Chemother. 1996 Sep; 40(9):1995-7. PMID: 8878569; PMCID: PMC163461.
    75. Burke TW, Levenback C, Tornos C, Morris M, Wharton JT, Gershenson DM. Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study. Gynecol Oncol. 1996 Aug; 62(2):169-73. PMID: 8751545.
      View in: PubMed
    76. Wolf JK, Levenback C, Malpica A, Morris M, Burke T, Mitchell MF. Adenocarcinoma in situ of the cervix: significance of cone biopsy margins. Obstet Gynecol. 1996 Jul; 88(1):82-6. PMID: 8684768.
      View in: PubMed
    77. Levenback C, Morris M, Burke TW, Gershenson DM, Wolf JK, Wharton JT. Groin dissection practices among gynecologic oncologists treating early vulvar cancer. Gynecol Oncol. 1996 Jul; 62(1):73-7. PMID: 8690296.
      View in: PubMed
    78. Burke TW, Tortolero-Luna G, Malpica A, Baker VV, Whittaker L, Johnson E, Follen Mitchell M. Endometrial hyperplasia and endometrial cancer. Obstet Gynecol Clin North Am. 1996 Jun; 23(2):411-56. PMID: 8784886.
      View in: PubMed
    79. Gershenson DM, Morris M, Burke TW, Levenback C, Matthews CM, Wharton JT. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Obstet Gynecol. 1996 Apr; 87(4):527-31. PMID: 8602303.
      View in: PubMed
    80. Currie J, Blessing JA, Muss HB, Fowler J, Berman M, Burke TW. Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol. 1996 Apr; 61(1):27-30. PMID: 8626112.
      View in: PubMed
    81. Segreti EM, Levenback C, Morris M, Lucas KR, Gershenson DM, Burke TW. A comparison of end and loop colostomy for fecal diversion in gynecologic patients with colonic fistulas. Gynecol Oncol. 1996 Jan; 60(1):49-53. PMID: 8557227.
      View in: PubMed
    82. Sweeten KM, Gershenson DM, Burke TW, Morris M, Levenback C, Silva EG. Salvage chemotherapy for refractory transitional cell carcinoma of the ovary (TCC). Gynecol Oncol. 1995 Nov; 59(2):211-5. PMID: 7590475.
      View in: PubMed
    83. Reddoch JM, Burke TW, Morris M, Tornos C, Levenback C, Gershenson DM. Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme. Gynecol Oncol. 1995 Nov; 59(2):221-5. PMID: 7590477.
      View in: PubMed
    84. Levenback C, Burke TW, Morris M, Malpica A, Lucas KR, Gershenson DM. Potential applications of intraoperative lymphatic mapping in vulvar cancer. Gynecol Oncol. 1995 Nov; 59(2):216-20. PMID: 7590476.
      View in: PubMed
    85. Eifel PJ, Morris M, Burke TW, Levenback C, Gershenson DM. Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. Gynecol Oncol. 1995 Oct; 59(1):51-6. PMID: 7557615.
      View in: PubMed
    86. Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol. 1995 Oct; 59(1):38-44. PMID: 7557613.
      View in: PubMed
    87. Kieback DG, Burke TW. Modified instruments for mobilization of the ureters and parametrial transsection during radical hysterectomy. Ann Surg Oncol. 1995 Sep; 2(5):435-9. PMID: 7496839.
      View in: PubMed
    88. Gershenson DM, Morris M, Burke TW, Levenback C, Kavanagh JJ, Fromm GL, Silva EG, Warner D, Wharton JT. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer. Gynecol Oncol. 1995 Sep; 58(3):349-55. PMID: 7672700.
      View in: PubMed
    89. Miller B, Morris M, Levenback C, Burke TW, Gershenson DM. Pelvic exenteration for primary and recurrent vulvar cancer. Gynecol Oncol. 1995 Aug; 58(2):202-5. PMID: 7622106.
      View in: PubMed
    90. Chuang L, Burke TW, Tornos C, Marino BD, Mitchell MF, Tortolero-Luna G, Levenback C, Morris M, Gershenson DM. Staging laparotomy for endometrial carcinoma: assessment of retroperitoneal lymph nodes. Gynecol Oncol. 1995 Aug; 58(2):189-93. PMID: 7622103.
      View in: PubMed
    91. Malpica A, Tornos C, Burke TW, Silva EG. Low-stage clear-cell carcinoma of the endometrium. Am J Surg Pathol. 1995 Jul; 19(7):769-74. PMID: 7793474.
      View in: PubMed
    92. Bicher A, Levenback C, Burke TW, Morris M, Warner D, DeJesus Y, Gershenson DM. Infusion site soft-tissue injury after paclitaxel administration. Cancer. 1995 Jul 1; 76(1):116-20. PMID: 8630862.
      View in: PubMed
    93. Bicher A, Levenback C, Silva EG, Burke TW, Morris M, Gershenson DM. Ovarian malignant mixed müllerian tumors treated with platinum-based chemotherapy. Obstet Gynecol. 1995 May; 85(5 Pt 1):735-9. PMID: 7724104.
      View in: PubMed
    94. Gabel C, Eifel PJ, Tornos C, Burke TW. Radiation recall reaction to idarubicin resulting in vaginal necrosis. Gynecol Oncol. 1995 May; 57(2):266-9. PMID: 7729748.
      View in: PubMed
    95. Burke TW, Levenback C, Coleman RL, Morris M, Silva EG, Gershenson DM. Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol. 1995 May; 57(2):215-20. PMID: 7729737.
      View in: PubMed
    96. Burke TW, Morris M, Roh MS, Levenback C, Gershenson DM. Perineal reconstruction using single gracilis myocutaneous flaps. Gynecol Oncol. 1995 May; 57(2):221-5. PMID: 7729738.
      View in: PubMed
    97. Morris M, Eifel PJ, Burke TW, McNamara MM, Levenback C, Kavanagh JJ, Gershenson DM. Treatment of locally advanced cervical cancer with concurrent radiation and intra-arterial chemotherapy. Gynecol Oncol. 1995 Apr; 57(1):72-8. PMID: 7705704.
      View in: PubMed
    98. Miller B, Umpierre S, Tornos C, Burke T. Histologic characterization of uterine papillary serous adenocarcinoma. Gynecol Oncol. 1995 Mar; 56(3):425-9. PMID: 7705679.
      View in: PubMed
    99. Miller B, Morris M, Gershenson DM, Levenback CL, Burke TW. Intestinal fistulae formation following pelvic exenteration: a review of the University of Texas M. D. Anderson Cancer Center experience, 1957-1990. Gynecol Oncol. 1995 Feb; 56(2):207-10. PMID: 7896187.
      View in: PubMed
    100. Marino BD, Burke TW, Tornos C, Chuang L, Mitchell MF, Tortolero-Luna G, Morris M, Gershenson DM. Staging laparotomy for endometrial carcinoma: assessment of peritoneal spread. Gynecol Oncol. 1995 Jan; 56(1):34-8. PMID: 7821845.
      View in: PubMed
    101. Burke TW, Fowler WC, Morrow CP. Clinical aspects of risk in women with endometrial carcinoma. J Cell Biochem Suppl. 1995; 23:131-6. PMID: 8747387.
      View in: PubMed
    102. Burke TW, Morris M, Levenback C, Gershenson DM, Wharton JT. Closure of complex vulvar defects using local rhomboid flaps. Obstet Gynecol. 1994 Dec; 84(6):1043-7. PMID: 7970463.
      View in: PubMed
    103. Lehman E, Gershenson DM, Burke TW, Levenback C, Silva EG, Morris M. Salvage surgery for chemorefractory gestational trophoblastic disease. J Clin Oncol. 1994 Dec; 12(12):2737-42. PMID: 7989951.
      View in: PubMed
    104. Levenback C, Eifel PJ, Burke TW, Morris M, Gershenson DM. Hemorrhagic cystitis following radiotherapy for stage Ib cancer of the cervix. Gynecol Oncol. 1994 Nov; 55(2):206-10. PMID: 7959285.
      View in: PubMed
    105. Munkarah A, Gershenson DM, Levenback C, Silva EG, Messing MJ, Morris M, Burke TW. Salvage surgery for chemorefractory ovarian germ cell tumors. Gynecol Oncol. 1994 Nov; 55(2):217-23. PMID: 7959287.
      View in: PubMed
    106. Burke TW, Gershenson DM, Morris M, Stringer CA, Levenback C, Tortolero-Luna G, Baker VV. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol. 1994 Oct; 55(1):47-50. PMID: 7959265.
      View in: PubMed
    107. Coleman RL, Keeney ED, Freedman RS, Burke TW, Eifel PJ, Rutledge FN. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol. 1994 Oct; 55(1):29-35. PMID: 7959262.
      View in: PubMed
    108. Levenback C, Burke TW, Gershenson DM, Morris M, Malpica A, Ross MI. Intraoperative lymphatic mapping for vulvar cancer. Obstet Gynecol. 1994 Aug; 84(2):163-7. PMID: 8041523.
      View in: PubMed
    109. Bicher A, Sahin AA, Burke TW. Metastatic cervical cancer presenting as cholecystitis. Gynecol Oncol. 1994 Aug; 54(2):250-3. PMID: 8063256.
      View in: PubMed
    110. Tornos C, Silva EG, Khorana SM, Burke TW. High-stage endometrioid carcinoma of the ovary. Prognostic significance of pure versus mixed histologic types. Am J Surg Pathol. 1994 Jul; 18(7):687-93. PMID: 8017563.
      View in: PubMed
    111. Morris M, Gershenson DM, Burke TW, Mitchell MF, Levenback C, Atkinson N, Wharton JT. A phase II study of carboplatin and cisplatin in advanced or recurrent squamous carcinoma of the uterine cervix. Gynecol Oncol. 1994 May; 53(2):234-8. PMID: 8188085.
      View in: PubMed
    112. Umpierre SA, Burke TW, Tornos C, Ordonez N, Levenback C, Morris M. Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors. Int J Gynecol Pathol. 1994 Apr; 13(2):127-30. PMID: 8005733.
      View in: PubMed
    113. Levenback C, Gershenson DM, McGehee R, Eifel PJ, Morris M, Burke TW. Enterovesical fistula following radiotherapy for gynecologic cancer. Gynecol Oncol. 1994 Mar; 52(3):296-300. PMID: 8157186.
      View in: PubMed
    114. Burke TW, Morris M. Secondary cytoreductive surgery for ovarian cancer. Obstet Gynecol Clin North Am. 1994 Mar; 21(1):167-78. PMID: 8015762.
      View in: PubMed
    115. Burke TW, Wolfson AH. Limited endometrial carcinoma: adjuvant therapy. Semin Oncol. 1994 Feb; 21(1):84-90. PMID: 8310314.
      View in: PubMed
    116. Burke TW, Munkarah A, Kavanagh JJ, Morris M, Levenback C, Tornos C, Gershenson DM. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol. 1993 Dec; 51(3):397-400. PMID: 8112651.
      View in: PubMed
    117. Coleman RL, Burke TW, Morris M, Eifel PJ, Hallum AV, Wallace S, Tornos C. Intraoperative radiographs to confirm the adequacy of lymph node resection in patients with suspicious lymphangiograms. Gynecol Oncol. 1993 Dec; 51(3):362-7. PMID: 8112646.
      View in: PubMed
    118. Kupelian PA, Eifel PJ, Tornos C, Burke TW, Delclos L, Oswald MJ. Treatment of endometrial carcinoma with radiation therapy alone. Int J Radiat Oncol Biol Phys. 1993 Nov 15; 27(4):817-24. PMID: 8244810.
      View in: PubMed
    119. Roman LD, Morris M, Mitchell MF, Eifel PJ, Burke TW, Atkinson EN. Prognostic factors for patients undergoing simple hysterectomy in the presence of invasive cancer of the cervix. Gynecol Oncol. 1993 Aug; 50(2):179-84. PMID: 8375732.
      View in: PubMed
    120. Miller B, Morris M, Rutledge F, Mitchell MF, Atkinson EN, Burke TW, Wharton JT. Aborted exenterative procedures in recurrent cervical cancer. Gynecol Oncol. 1993 Jul; 50(1):94-9. PMID: 8349169.
      View in: PubMed
    121. Matthews CM, Burke TW, Tornos C, Eifel PJ, Atkinson EN, Stringer CA, Morris M, Silva EG. Stage I cervical adenocarcinoma: prognostic evaluation of surgically treated patients. Gynecol Oncol. 1993 Apr; 49(1):19-23. PMID: 8482554.
      View in: PubMed
    122. Gershenson DM, Mitchell MF, Atkinson N, Silva EG, Burke TW, Morris M, Kavanagh JJ, Warner D, Wharton JT. Age contrasts in patients with advanced epithelial ovarian cancer. The M.D. Anderson Cancer Center experience. Cancer. 1993 Jan 15; 71(2 Suppl):638-43. PMID: 8420688.
      View in: PubMed
    123. Gershenson DM, Mitchell MF, Atkinson N, Silva EG, Kavanagh JJ, Morris M, Burke TW, Warner D, Wharton JT. The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: "maintenance" therapy reconsidered. Gynecol Oncol. 1992 Oct; 47(1):7-13. PMID: 1427404.
      View in: PubMed
    124. Morris M, Gershenson DM, Eifel P, Silva EG, Mitchell MF, Burke TW, Wharton JT. Treatment of small cell carcinoma of the cervix with cisplatin, doxorubicin, and etoposide. Gynecol Oncol. 1992 Oct; 47(1):62-5. PMID: 1330847.
      View in: PubMed
    125. Levenback C, Burke TW, Silva E, Morris M, Gershenson DM, Kavanagh JJ, Wharton JT. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol. 1992 Sep; 46(3):317-21. PMID: 1526508.
      View in: PubMed
    126. Tornos C, Silva EG, el-Naggar A, Burke TW. Aggressive stage I grade 1 endometrial carcinoma. Cancer. 1992 Aug 15; 70(4):790-8. PMID: 1643610.
      View in: PubMed
    127. Matthews CM, Morris M, Burke TW, Gershenson DM, Wharton JT, Rutledge FN. Pelvic exenteration in the elderly patient. Obstet Gynecol. 1992 May; 79(5 ( Pt 1)):773-7. PMID: 1565364.
      View in: PubMed
    128. Roman LD, Morris M, Eifel PJ, Burke TW, Gershenson DM, Wharton JT. Reasons for inappropriate simple hysterectomy in the presence of invasive cancer of the cervix. Obstet Gynecol. 1992 Apr; 79(4):485-9. PMID: 1553163.
      View in: PubMed
    129. Kelley JL, Burke TW, Tornos C, Morris M, Gershenson DM, Silva EG, Wharton JT. Minimally invasive vulvar carcinoma: an indication for conservative surgical therapy. Gynecol Oncol. 1992 Mar; 44(3):240-4. PMID: 1541436.
      View in: PubMed
    130. Burke TW. Changing surgical approaches to vulvar cancer. Curr Opin Obstet Gynecol. 1992 Feb; 4(1):86-90. PMID: 1543835.
      View in: PubMed
    131. Burke TW. Factors affecting recurrence and survival in stage I carcinoma of the uterine cervix. Oncology (Williston Park). 1992 Feb; 6(2):111-6; discussion 118-9; 122. PMID: 1532496.
      View in: PubMed
    132. Rosenblum MG, Kavanagh JJ, Burke TW, Wharton JT, Cunningham JE, Shanken LJ, Silva EG, Thompson L, Cheung L, Lamki L, et al. Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration. J Natl Cancer Inst. 1991 Nov 20; 83(22):1629-36. PMID: 1721093.
      View in: PubMed
    133. Morris M, Gershenson DM, Burke TW, Wharton JT, Copeland LJ, Rutledge FN. Splenectomy in gynecologic oncology: indications, complications, and technique. Gynecol Oncol. 1991 Nov; 43(2):118-22. PMID: 1743552.
      View in: PubMed
    134. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol. 1991 Aug; 42(2):146-50. PMID: 1894174.
      View in: PubMed
    135. Eifel PJ, Burke TW, Delclos L, Wharton JT, Oswald MJ. Early stage I adenocarcinoma of the uterine cervix: treatment results in patients with tumors less than or equal to 4 cm in diameter. Gynecol Oncol. 1991 Jun; 41(3):199-205. PMID: 1869095.
      View in: PubMed
    136. Roman LD, Mitchell MF, Burke TW, Silva EG. Unsuspected invasive squamous cell carcinoma of the vulva in young women. Gynecol Oncol. 1991 May; 41(2):182-5. PMID: 2050311.
      View in: PubMed
    137. Burke TW, Stringer CA, Morris M, Freedman RS, Gershenson DM, Kavanagh JJ, Edwards CL. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol. 1991 Mar; 40(3):264-7. PMID: 2013451.
      View in: PubMed
    138. Smiley LM, Burke TW, Silva EG, Morris M, Gershenson DM, Wharton JT. Prognostic factors in stage IB squamous cervical cancer patients with low risk for recurrence. Obstet Gynecol. 1991 Feb; 77(2):271-5. PMID: 1988891.
      View in: PubMed
    139. Kline RC, Wharton JT, Atkinson EN, Burke TW, Gershenson DM, Edwards CL. Endometrioid carcinoma of the ovary: retrospective review of 145 cases. Gynecol Oncol. 1990 Dec; 39(3):337-46. PMID: 2258081.
      View in: PubMed
    140. Morris M, Gershenson DM, Burke TW, Kavanagh JJ, Silva EG, Wharton JT. Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Obstet Gynecol. 1990 Dec; 76(6):1020-4. PMID: 2234710.
      View in: PubMed
    141. Burke TW, Stringer CA, Gershenson DM, Edwards CL, Morris M, Wharton JT. Radical wide excision and selective inguinal node dissection for squamous cell carcinoma of the vulva. Gynecol Oncol. 1990 Sep; 38(3):328-32. PMID: 2227543.
      View in: PubMed
    142. Stringer CA, Gershenson DM, Burke TW, Edwards CL, Gordon AN, Wharton JT. Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis. Gynecol Oncol. 1990 Sep; 38(3):305-8. PMID: 2227540.
      View in: PubMed
    143. Rellihan MA, Dooley DP, Burke TW, Berkland ME, Longfield RN. Rapidly progressing cervical cancer in a patient with human immunodeficiency virus infection. Gynecol Oncol. 1990 Mar; 36(3):435-8. PMID: 2318457.
      View in: PubMed
    144. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol. 1990 Feb; 36(2):189-91. PMID: 2298408.
      View in: PubMed
    145. Burke TW, Heller PB, Woodward JE, Davidson SA, Hoskins WJ, Park RC. Treatment failure in endometrial carcinoma. Obstet Gynecol. 1990 Jan; 75(1):96-101. PMID: 2296431.
      View in: PubMed
    146. Doering DL, Barnhill DR, Weiser EB, Burke TW, Woodward JE, Park RC. Intraoperative evaluation of depth of myometrial invasion in stage I endometrial adenocarcinoma. Obstet Gynecol. 1989 Dec; 74(6):930-3. PMID: 2586959.
      View in: PubMed
    147. Styron SL, Burke TW, Linville WK. Low-grade endometrial stromal sarcoma recurring over three decades. Gynecol Oncol. 1989 Nov; 35(2):275-8. PMID: 2807024.
      View in: PubMed
    148. Collins HS, Burke TW, Woodward JE, Spurlock JW, Heller PB. Widespread lymph node metastases in a patient with microinvasive cervical carcinoma. Gynecol Oncol. 1989 Aug; 34(2):219-21. PMID: 2753428.
      View in: PubMed
    149. Taylor SW, Barnhill DR, Burke TW, Linville WK, Yevich I. Methotrexate-induced erythema multiforme. Gynecol Oncol. 1989 Jun; 33(3):376-8. PMID: 2722066.
      View in: PubMed
    150. Collins HS, Burke TW, Heller PB, Olson TA, Woodward JE, Park RC. Endodermal sinus tumor of the infant vagina treated exclusively by chemotherapy. Obstet Gynecol. 1989 Mar; 73(3 Pt 2):507-9. PMID: 2464779.
      View in: PubMed
    151. Culling RD, Deppe SA, Goglin WK, Ducey JP, Burke TW. Continuous thoracic epidural analgesia for the control of pain associated with pleural sclerosis. Gynecol Oncol. 1989 Jan; 32(1):76-8. PMID: 2909451.
      View in: PubMed
    152. Weiser EB, Burke TW, Heller PB, Woodward J, Hoskins WJ, Park RC. Determinants of survival of patients with epithelial ovarian carcinoma following whole abdomen irradiation (WAR). Gynecol Oncol. 1988 Jun; 30(2):201-8. PMID: 3371745.
      View in: PubMed
    153. Hunter VP, Burke TW, Crooks LA. Retroperitoneal nerve sheath tumors: an unusual cause of pelvic mass. Obstet Gynecol. 1988 Jun; 71(6 Pt 2):1050-2. PMID: 3374919.
      View in: PubMed
    154. Barnhill DR, Boling R, Nobles W, Crooks L, Burke T. Vulvar dermatofibrosarcoma protuberans. Gynecol Oncol. 1988 May; 30(1):149-52. PMID: 3366391.
      View in: PubMed
    155. Nash JD, Burke TW, Woodward JE, Hall KL, Weiser EB, Heller PB. Diagnosis of recurrent gynecologic malignancy with fine-needle aspiration cytology. Obstet Gynecol. 1988 Mar; 71(3 Pt 1):333-7. PMID: 3347417.
      View in: PubMed
    156. Burke TW, Heller PB, Hoskins WJ, Weiser EB, Nash JD, Park RC. Evaluation of the scalene lymph nodes in primary and recurrent cervical carcinoma. Gynecol Oncol. 1987 Nov; 28(3):312-7. PMID: 3678980.
      View in: PubMed
    157. Barnhill D, Hoskins W, Burke T, Weiser E, Heller P, Park R. The treatment of retroperitoneal fibromatosis with medroxyprogesterone acetate. Obstet Gynecol. 1987 Sep; 70(3 Pt 2):502-4. PMID: 2957621.
      View in: PubMed
    158. Spurlock JW, Burke TW, Dunn NP, Heller PB, Collins HS, Park RC. Calyceal rupture with perirenal urinoma in a patient with cervical carcinoma. Obstet Gynecol. 1987 Sep; 70(3 Pt 2):511-3. PMID: 3627616.
      View in: PubMed
    159. Gschwend J, Burke TW, Woodward JE, Heller PB. Retroperitoneal teratoma presenting as an abdominal-pelvic mass. Obstet Gynecol. 1987 Sep; 70(3 Pt 2):500-2. PMID: 3627612.
      View in: PubMed
    160. Burke TW, Hoskins WJ, Heller PB, Shen MC, Weiser EB, Park RC. Clinical patterns of tumor recurrence after radical hysterectomy in stage IB cervical carcinoma. Obstet Gynecol. 1987 Mar; 69(3 Pt 1):382-5. PMID: 3822285.
      View in: PubMed
    161. Nash JD, Burke TW, Hoskins WJ. Biologic course of cervical human papillomavirus infection. Obstet Gynecol. 1987 Feb; 69(2):160-2. PMID: 3027635.
      View in: PubMed
    162. Hoskins WJ, Burke TW, Weiser EB, Heller PB, Grayson J, Park RC. Right hemicolectomy and ileal resection with primary reanastomosis for irradiation injury of the terminal ileum. Gynecol Oncol. 1987 Feb; 26(2):215-24. PMID: 3804037.
      View in: PubMed
    163. Burke TW, Weiser EB, Hoskins WJ, Heller PB, Nash JD, Park RC. End colostomy using the end-to-end anastomosis instrument. Obstet Gynecol. 1987 Feb; 69(2):156-9. PMID: 3808502.
      View in: PubMed
    164. Burke TW, Hoskins WJ, Heller PB, Bibro MC, Weiser EB, Park RC. Prognostic factors associated with radical hysterectomy failure. Gynecol Oncol. 1987 Feb; 26(2):153-9. PMID: 3804033.
      View in: PubMed
    165. 3 lessons from this year's quest for quality applicants. Hospitals and Health Networks. 90.
    166. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Obstetrical and Gynecological Survey. 45:558-559.
    167. Foreword. Gynecologic Oncology. 112.
    168. Radiotherapy for recurrent small cell carcinoma of the ovary. Gynecologic Oncology Case Reports. 11:23-25.
    169. Primary treatment failure in patients with malignant ovarian germ cell neoplasms. International Journal of Gynecological Cancer. 2:295-300.
    170. Endometrial cancer. 109-117.
    171. Intraoperative lymphatic mapping for vulvar cancer. ACOG Current Journal Review. 8:41.
    172. Prognostic factors associated with radical hysterectomy failure. Obstetrical and Gynecological Survey. 42:585-587.
    173. Gynecologic malignancies in pregnancy. Cancer Bulletin. 46:424-431.
    174. Clinical and pathological risk factors in stage I cervical cancer. Clinical Consultations in Obstetrics and Gynecology. 7:118-125.
    175. Small bowel procedures. Operative Techniques in Gynecologic Surgery. 6:64-69.
    176. Advanced-Stage Vulvar Cancer. 105-112.
    177. Treatment options in stage IB cervical cancer. Seminars in Radiation Oncology. 4:34-40.
    178. Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide for early-stage high-risk endometrial cancer. Obstetrical and Gynecological Survey. 46:168-169.
    179. 60 Years of survival outcomes at the university of Texas MD Anderson cancer center.
    180. Radical wide excision and selective inguinal node dissection for squamous cell carcinoma of the vulva. Obstetrical and Gynecological Survey. 46:166-167.
    181. Identification of primary chromosome abnormalities in a patient with endometrial carcinoma. International Journal of Oncology. 7:765-772.
    BURKE's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description